Transferrin receptor binding valency determines the circulating half-life and weight-loss efficacy of Fc-FGF21 in TfR-humanized mice
This study demonstrates that while engineering Fc-FGF21 to bind the human transferrin receptor (hTfR) aims to enhance blood-brain barrier transport, the resulting bivalent hTfR engagement in humanized mice drastically shortens the protein's circulating half-life and abolishes its weight-loss efficacy, highlighting a critical design trade-off where systemic clearance by the shuttle receptor compromises the therapeutic activity of metabolic hormones.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human body relies on a sophisticated network of chemical messengers to manage energy, hunger, and weight. Among these, a hormone called fibroblast growth factor 21, or FGF21, acts as a powerful regulator, signaling the body to burn fat and improve how it handles sugar. This hormone works by traveling through the bloodstream to reach both the organs and the brain, where it helps coordinate the body's response to food. However, a significant hurdle exists for treating obesity with such hormones: the brain is protected by a highly selective barrier known as the blood-brain barrier. This barrier acts like a strict security checkpoint, preventing most large molecules in the blood from entering the brain tissue. Because the receptors that FGF21 needs to bind with are found in low numbers within the brain, scientists have long wondered if forcing more of the hormone across this barrier would make it a far more effective weight-loss treatment.
To test this idea, researchers engineered a new version of the hormone designed to hitch a ride across the brain's security checkpoint. They attached FGF21 to a molecular vehicle, a modified fragment of an antibody, that was programmed to recognize and bind to the transferrin receptor. This receptor is abundant on the surface of blood vessels in the brain and normally functions to ferry iron into the central nervous system. The logic was sound: if the hormone could grab onto this receptor, it might be pulled across the barrier and delivered deep into the brain, where it could exert its full metabolic power. The team created a fusion protein that carried two such binding arms, effectively giving the molecule a double grip on the receptor, and tested it in mice that had been genetically modified to carry the human version of this receptor.
The results, however, revealed a surprising and counterintuitive flaw in the design. When the researchers administered this double-armed protein to mice with humanized receptors, the treatment failed completely to reduce body weight. In fact, the engineered hormone vanished from the bloodstream almost immediately, lasting only about four hours before being cleared from the body. This was a dramatic drop compared to the standard version of the drug, which remained active for nearly fifty hours. The rapid disappearance meant the hormone never had enough time to work, and the intended benefit of increased brain delivery was lost. The researchers found that the very mechanism designed to help the drug enter the brain was actually causing it to be trapped and destroyed by the body's own recycling systems. The double grip was too strong; instead of crossing the barrier, the molecule was held fast by the receptors on the blood vessel walls and dragged into the cells to be broken down.
Undeterred, the team adjusted their strategy to see if a gentler approach would work. They redesigned the protein so that it possessed only a single binding arm for the receptor, rather than two. This change reduced the strength of the grip, theoretically allowing the molecule to be released and transported across the barrier more easily. In the mice with humanized receptors, this single-armed version performed better than the double-armed one. It stayed in the bloodstream longer, lasting about twelve hours, and it managed to lower body weight, though not as effectively as the standard drug without the receptor-binding feature. The single grip was enough to allow some transport, but it still caused the drug to be cleared from the system faster than desired. The researchers also tested mice with only one copy of the human receptor gene, hoping that fewer receptors in the body would slow down the clearance process. This did not help; the drug was still removed quickly, and the weight-loss effect remained limited.
These findings suggest that for a hormone like FGF21, which relies on sustained presence in the blood to do its job, the strategy of using a strong, dual-sided connection to a brain shuttle is counterproductive. The study indicates that the most critical factor for the drug's success is not necessarily how much of it reaches the brain, but how long it remains active in the entire body. When the shuttle binds too tightly or with too many points of contact, it acts as a sink that pulls the drug out of circulation and destroys it before it can work. The research highlights a difficult balancing act in drug design: the need to cross the brain barrier must be weighed against the risk of losing the drug to rapid clearance. The authors conclude that future designs for delivering metabolic hormones to the brain must prioritize keeping the drug in the bloodstream for a sufficient duration, perhaps by using different types of shuttles or by engineering the connection to be weaker, ensuring that the molecule survives long enough to treat the condition effectively.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.